← Back to Analyst Consensus 
PRLD Buy
Prelude Therapeutics Inc
Current Price —
Implied Upside —
Analysts 11
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 10, 2026 (15 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Sep 17, 2026 | JP Morgan | initiate | — → Overweight | — | 54% |
| Jul 29, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| May 15, 2026 | Goldman Sachs | initiate | — → Early-Stage Biotech | — | 54% |
| May 4, 2026 | D. Boral Capital | initiate | — → Buy | — | 34% |
| Apr 27, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Mar 11, 2026 | Citizens | maintain | Market Outperform → Market Outperform | — | 47% |
| Sep 23, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $5 | 44% |
| Aug 18, 2025 | JMP Securities | maintain | Market Outperform → Market Outperform | $3 | 53% |
| May 5, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $5 | 44% |
| Apr 29, 2025 | JMP Securities | reiterate | Market Outperform → Market Outperform | $4 | 53% |
| Apr 8, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $5 | 44% |
| Mar 12, 2025 | Citizens Capital Markets | reiterate | Market Outperform → Market Outperform | $4 | 49% |
| Dec 11, 2024 | JMP Securities | reiterate | Market Outperform → Market Outperform | $4 | 53% |
| Nov 8, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $5 | 44% |
| Oct 28, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $5 | 44% |
| Sep 19, 2024 | HC Wainwright & Co. | upgrade | Neutral → Buy | $5 | 44% |
| Sep 16, 2024 | JMP Securities | reiterate | Market Outperform → Market Outperform | $7 | 53% |
| Sep 16, 2024 | HC Wainwright & Co. | reiterate | Neutral → Neutral | $5 | 44% |
| Sep 10, 2024 | HC Wainwright & Co. | reiterate | Neutral → Neutral | $5 | 44% |
| Aug 15, 2024 | HC Wainwright & Co. | reiterate | Neutral → Neutral | $5 | 44% |
| Mar 13, 2024 | JMP Securities | initiate | — → Market Outperform | $7 | 53% |
| Feb 20, 2024 | HC Wainwright & Co. | downgrade | Buy → Neutral | $5 | 44% |
| Dec 19, 2023 | Morgan Stanley | downgrade | Equal-Weight → Underweight | $4 | 54% |
| Nov 7, 2023 | HC Wainwright & Co. | maintain | Buy → Buy | $5 | 44% |
| Oct 19, 2023 | HC Wainwright & Co. | maintain | Buy → Buy | $6 | 44% |
| Aug 17, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $17 | 44% |
| Aug 4, 2023 | Morgan Stanley | reiterate | Equal-Weight → Equal-Weight | $10 | 54% |
| Aug 4, 2023 | Barclays | maintain | Equal-Weight → Equal-Weight | $5 | 53% |
| Mar 17, 2023 | HC Wainwright & Co. | maintain | — → Buy | $17 | 44% |
| Nov 21, 2022 | B of A Securities | downgrade | Neutral → Underperform | $6 | 53% |
| Nov 17, 2022 | HC Wainwright & Co. | maintain | — → Buy | $15 | 44% |
| Nov 15, 2022 | Morgan Stanley | maintain | — → Equal-Weight | $10 | 54% |
| Sep 9, 2022 | Morgan Stanley | downgrade | Overweight → Equal-Weight | $11 | 54% |
| Jul 29, 2022 | Jefferies | initiate | — → Buy | $9 | 52% |
| May 12, 2022 | HC Wainwright & Co. | maintain | — → Buy | $16 | 44% |
| Mar 17, 2022 | Morgan Stanley | maintain | — → Overweight | $19 | 54% |
| Mar 15, 2022 | B of A Securities | downgrade | Buy → Neutral | $10 | 53% |
| Feb 28, 2022 | Barclays | downgrade | Overweight → Equal-Weight | $12 | 53% |
| Nov 17, 2021 | Barclays | maintain | — → Overweight | $20 | 53% |
| Oct 11, 2021 | Morgan Stanley | upgrade | Equal-Weight → Overweight | $35 | 54% |
| Oct 8, 2021 | Barclays | maintain | — → Overweight | $33 | 53% |
| Jul 27, 2021 | B of A Securities | upgrade | Neutral → Buy | $60 | 53% |
| Apr 26, 2021 | HC Wainwright & Co. | initiate | — → Buy | $62 | 44% |
| Mar 17, 2021 | Morgan Stanley | maintain | — → Equal-Weight | $60 | 54% |
| Dec 16, 2020 | Morgan Stanley | maintain | — → Equal-Weight | $47 | 54% |
| Nov 12, 2020 | Morgan Stanley | maintain | — → Equal-Weight | $38 | 54% |
| Oct 20, 2020 | B of A Securities | initiate | — → Buy | $40 | 53% |
| Oct 20, 2020 | Goldman Sachs | initiate | — → Neutral | $37 | 54% |
| Oct 20, 2020 | Morgan Stanley | initiate | — → Equal-Weight | $0 | 54% |
Price Target Trend
Apr 15, 2026 Latest: $9.2 Oct 24, 2026
EPS Estimates
+1q $-0.15
Lo: $-0.18 Hi: $-0.14
3 analysts ▲1
0q $-0.14
Lo: $-0.16 Hi: $-0.13
3 analysts ▲1
0y $-0.57
Lo: $-0.61 Hi: $-0.54
4 analysts ▲1
+1y $-0.58
Lo: $-0.79 Hi: $-0.11
4 analysts ▲1
Cross-Platform Signals
No cross-platform signals in the last 90 days